BioMarin Pharmaceutical Inc. (BMRN) Fair Value 2026

BMRN · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.6 /10

32 fundamental signals · 10 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-27, BioMarin Pharmaceutical Inc. (BMRN) trades at $65.29, versus a $43.14 median fair value across its 10 active models — 33.9% below the current price. QOC: 8.6/10. Value Trap Risk: 0/100 (SAFE). 10/13 models active. Within that set, the Bayesian DCF component alone returns $108.21.

Key Facts

Ticker
BMRN
Price
$65.29
Quality Score
8.6/10
Value Trap Risk
0/100
Models Active
10/13
Last Updated
Strength: Bayesian DCF suggests +65.7% upside with 72% confidence
Risk: Majority of models suggest overvaluation

Is BioMarin Pharmaceutical Inc. (BMRN) Undervalued or Overvalued in 2026?

According to CirclFi’s 10-model valuation engine, BioMarin Pharmaceutical Inc. (BMRN) appears overvalued as of : the median of 10 independent fair value estimates is $43.14, 33.9% below the current price of $65.29. Estimates range from $2.01 to $108.21. BMRN scores 8.6/10 on fundamental quality and 0/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. BMRN’s -33.9% gap is wider than that market norm, and the Biotechnology sector median is -64.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy BioMarin Pharmaceutical Inc. Stock in 2026? →

What Fair Value Does Each Model Give BMRN?

10 Intrinsic Value Models vs. Current Price ($65.29)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $108.21 +65.7%
Intrinsic · High Conviction
 $2.01 -96.9%
Ensemble · Low Conviction
 $49.37 -24.4%
Scenario · High Conviction
 $7.11 -89.1%
Unlock the Full Matrix

Access 6 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is BMRN's Fair Value Range?

Spread across 10 independent models · $2.01 to $108.21

CirclFi's 10 active models place BioMarin Pharmaceutical Inc. (BMRN) between $2.01 and $108.21 per share, a spread of 246% of the median. The median of that range — $43.14 — is the fair value CirclFi publishes for BMRN, against a current price of $65.29.

Low · EPVHigh · Bayesian DCF
$2.01median $43.14$108.21
Where the range comes from
Most bearish modelEarnings Power Value (EPV)$2.01
Most bullish modelBayesian DCF$108.21
Model agreement2 bullish · 8 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for BMRN. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on BMRN, not a CirclFi price target. How each model works →

What Is BioMarin Pharmaceutical Inc. (BMRN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, BioMarin Pharmaceutical Inc.'s intrinsic value is estimated at $43.14, suggesting the stock is overvalued at its current price of $65.29. With 8 out of 10 models flagging downside (-33.9% vs price), the market may be pricing in unsustainable growth. The most optimistic model, Bayesian DCF, places fair value at $108.21 (+65.7%), while EPV — the most conservative — estimates $2.01 (-96.9%). This +162.7% gap reflects genuine analytical uncertainty about BioMarin Pharmaceutical Inc.'s intrinsic worth. Among models with highest confidence, Bayesian DCF, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About BMRN?

10 of 13 models are currently active for BMRN. Of these, 2 models suggest upside while 8 models suggest overvaluation. Taken together, their median fair value for BMRN is $43.14 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $108.21 on its own, implying +65.7% upside from the current price. See which stocks rank higher →

How Does BMRN Rank in Biotechnology?

Among 620 Biotechnology stocks, BMRN ranks #16 by Quality of Company score. CirclFi's QOC score of 8.6/10 evaluates 32 fundamental signals. A score of 8.6 places BMRN in the top tier.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, BioMarin Pharmaceutical Inc. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating BMRN should weigh these sector-specific dynamics alongside our model-derived fair values.

Is BMRN a Value Trap?

CirclFi's Value Trap algorithm assigns BMRN a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for BioMarin Pharmaceutical Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, BioMarin Pharmaceutical Inc.'s fundamental quality profile registers 8.6/10. This robust score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +162.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BMRN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BMRN's 10 active models, average confidence is 51%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy BioMarin Pharmaceutical Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

NAGENiagen Bioscience, Inc.QOC 8.6INVAInnoviva, Inc.QOC 8.6MDXGMiMedx Group, Inc.QOC 8.7ADMAADMA Biologics, Inc.QOC 8.5PTCTPTC Therapeutics, Inc.QOC 8.7REGNRegeneron Pharmaceuticals, Inc.QOC 8.5NAMSNewAmsterdam Pharma Company N.V.QOC 5.8DRUGBright Minds Biosciences Inc.QOC 5.0JBIOJade Biosciences, Inc.QOC 4.3EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: NAGE · INVA · MDXG · ADMA · PTCT · REGN · NAMS · DRUG · JBIO · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to BMRN?

7 companies across all industries closest to BMRN’s Quality of Company score of 8.6/10.

TSTenaris S.A.QOC 8.6ORCOrchid Island Capital, Inc.QOC 8.6ATMUAtmus Filtration Technologies Inc.QOC 8.6GENCGencor Industries, Inc.QOC 8.6MORNMorningstar, Inc.QOC 8.6BABBBAB, Inc.QOC 8.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: TS · ORC · ATMU · GENC · MORN · BABB · NVDA

Where Does BMRN Sit in CirclFi's Biotechnology Rankings?

BMRN is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About BioMarin Pharmaceutical Inc.’s Valuation?

What is BioMarin Pharmaceutical Inc.'s intrinsic value in 2026?

CirclFi puts BioMarin Pharmaceutical Inc. (BMRN)'s intrinsic value at $43.14 — the median of 10 independent model estimates as of 2026-08-27, ranging from $2.01 to $108.21. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $108.21 on its own. The Quality of Company score is 8.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BMRN overvalued or undervalued right now?

At $65.29, 2 of 10 active models suggest BMRN may be undervalued, while 8 indicate potential overvaluation. The median of all 10 fair value estimates is $43.14, 33.9% below the current price of $65.29 — a consensus view that BMRN is overvalued. The assessment depends on which methodology best fits BioMarin Pharmaceutical Inc.'s business model in Biotechnology.

What does a Quality of Company score of 8.6 mean for BMRN?

BioMarin Pharmaceutical Inc.'s QOC of 8.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on BMRN?

CirclFi analyzes BMRN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on BMRN?

Of the 10 models currently active on BMRN, Bayesian DCF is the most bullish at $108.21 per share, and Earnings Power Value (EPV) is the most bearish at $2.01. CirclFi's published fair value for BMRN is the median of that range, $43.14, not either extreme. The gap between the two ends equals 246% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is BMRN a value trap in 2026?

BioMarin Pharmaceutical Inc.'s Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 10-model valuation engine, BioMarin Pharmaceutical Inc. (BMRN) has a median fair value of $43.14 — 33.9% below the current price of $65.29 — as of 2026-08-27.” Source: circlfi.com/stock/BMRN/ · Methodology
Primary sources for this BMRN valuation
  • Financial statements: BioMarin Pharmaceutical Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001048477) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BMRN as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on BMRN.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

6 models hidden for BMRN Unlock All 10 — $39/mo